Condition: Giant Cell Arteritis · Sponsor: University of Pennsylvania
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission by Month 3, who experience a relapse within the first 12 months will have the option of receiving open-label abatacept for a maximum of 12 months.
This description comes directly from the study's public registry record.
Carol McAlear, MA · 7813214567 · cmcalear@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Hospital for Special Surgery | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Recruiting |
| University of British Columbia | Vancouver, British Columbia, Canada | Recruiting |
| St. Joseph's Healthcare | Hamilton, Ontario, Canada | Recruiting |
| Mount Sinai Hospital | Toronto, Ontario, Canada | Recruiting |
| Hôpital du Sacré-Coeur de Montréal Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04474847